|
Minerva Biolabs is committed to providing highest quality in products and services.
History
- 1999 The company was established in August 1999 as
a spin-off from the Robert-Koch Institute (RKI) in Berlin. Minerva Biolabs
GmbH started with innovative products for the effective diagnosis and
elimination of mycoplasma contamination in cell cultures and biopharmaceuticals.
- 2000 The transition to a quality management system
(QMS) in accordance with ISO 9001:2000 has been made in November 2000.
- 2001 Based on our experience with the production
of high quality and reliable diagnostics for biopharmaceutical quality
control, Minerva Biolabs transferred this know-how to the development
of clinical diagnostics for respiratory infections in 2001.
- 2004 The consequential expansion of our product range
led in the beginning of 2004 to the introduction of the worldwide first
bacterial diagnostic assay. Another innovative improvement followed
the same year by the integration of the Aqua Screen®
System into the portfolio of contamination control solutions. The Aqua
Screen® System provides a highly efficient method for
the filtration and detection of legionella in water. The transition
to a quality management system in accordance with ISO 13485:2003 has
been made in July 2004.
- 2005 As a direct result of our steadily expanding
product portfolio we are pleased to present our first product catalogue
at the beginning of 2005.
- 2006 Minerva Biolabs develops two new products for
the PCR Detection and the control of microbial contaminants. The PCR-Assays
Venor®GeM-qEP and Venor®GeM-qDual
can be used for the detection of mycoplasma DNA. Both products were
launched in the beginning of 2007.
- 2007 In June Minerva opens its new company building
with state of the art laboratories, production facilities and offices
on the site of the Vivantes-Wilhelm-Griesinger hospital in Berlin-Marzahn.
- 2008 In the beginning of the year Minerva Biolabs
expands his product range with two new clinical test kits Onar®MRSA
Screen and Onar®Tp. Onar®MRSA
Screen in vitro test system for quantitative and rapid PCR-based
detection of Methicillin-resistant Staphylococcus aureus in
clinical samples. Another innovative improvement followed with Mynox®Gold,
a further development of the classical Mynox®, which
was known for a very high elimination efficiency and low cytotoxicity.
Mynox®Gold is a combination of a standard antibiotic
and a biological reagent.
- 2009 Minerva Biolabs developed the PCR Assay Venor®GeM
Advance, a further development of the classical Venor®GeM
PCR Detection Kit. Another innovative development followed the same
year with Zell Shield - The Cell Culture Contamination Preventive, which
protects cell cultures from most intracellular and extracellular growing
gram negative and gram positive bacteria, mycoplasma, protozoon, fungi
and yeast.
|
